## M V N Kumar Talluri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3544512/publications.pdf

Version: 2024-02-01

47 papers

690 citations

623188 14 h-index 610482 24 g-index

47 all docs

47 docs citations

47 times ranked

760 citing authors

#	Article	IF	CITATIONS
1	Comprehensive degradation profiling and influence of different oxidizing reagents on tinoridine hydrochloride: Structural characterization of its degradation products using HPLC and HRMS. Rapid Communications in Mass Spectrometry, 2022, 36, e9210.	0.7	3
2	iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 33, 102351.	1.7	11
3	Characterization of stress degradation products of nintedanib by UPLC, UHPLC-Q-TOF/MS/MS and NMR: Evidence of a degradation product with a structure alert for mutagenicity. Journal of Pharmaceutical and Biomedical Analysis, 2021, 199, 114037.	1.4	12
4	Study on forced degradation behaviour of dofetilide by LC-PDA and Q-TOF/MS/MS: Mechanistic explanations of hydrolytic, oxidative and photocatalytic rearrangement of degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112985.	1.4	2
5	Identification and characterization of novel metabolites of nintedanib by ultraâ€performance liquid chromatography/quadrupole timeâ€ofâ€flight tandem mass spectrometry with ⟨i⟩in silico⟨/i⟩ toxicological assessment. Rapid Communications in Mass Spectrometry, 2020, 34, e8915.	0.7	5
6	Identification and characterization of degradation products of indacaterol using liquid chromatography/mass spectrometry. European Journal of Mass Spectrometry, 2020, 26, 425-431.	0.5	6
7	<i>In vivo</i> metabolic investigation of cetilistat in normal <i>versus</i> pseudoâ€germâ€free rats using UPLCâ€QTOFMS/MS and <i>in silico</i> toxicological evaluation of its metabolites. Biomedical Chromatography, 2020, 34, e4860.	0.8	2
8	A comprehensive study on rearrangement reactions in collisionâ€induced dissociation mass spectrometric fragmentation of protonated diphenyl and phenyl pyridyl ethers. Rapid Communications in Mass Spectrometry, 2019, 33, 1440-1448.	0.7	3
9	Identification and structural characterization of hydrolytic degradation products of alvimopan by LC/QTOF/MS/MS and NMR studies. Journal of Pharmaceutical and Biomedical Analysis, 2019, 165, 399-409.	1.4	7
10	Isolation and structural characterization of degradation products of afatinib dimaleate by LC-Q-TOF/MS/MS and NMR: cytotoxicity evaluation of afatinib and isolated degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2019, 166, 139-146.	1.4	13
11	In vitroand in vivo investigation of metabolic fate of riociguat by HPLC-Q-TOF/MS/MS and in silico evaluation of the metabolites by ADMET predictorâ,,¢. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 326-336.	1.4	21
12	Alcaftadine: Selective Separation and Characterization of Degradation Products by LC–QTOF-MS/MS. Chromatographia, 2018, 81, 631-638.	0.7	13
13	Characterization of forced degradation products of canagliflozine by liquid chromatography/quadrupole timeâ€ofâ€flight tandem mass spectrometry and ⟨i⟩in silico⟨/i⟩ toxicity predictions. Rapid Communications in Mass Spectrometry, 2018, 32, 212-220.	0.7	8
14	Study of forced degradation behaviour of cobicistat and atazanavir using LC/ESI/QTOF/MS; a combination of in-sourced and collision-induced dissociation for evaluation of the fragmentation patterns of degradation products. New Journal of Chemistry, 2018, 42, 19113-19128.	1.4	5
15	Development of a stability-indicating UPLC method for terconazole and characterization of the acidic and oxidative degradation products by UPLC-Q-TOF/MS/MS and NMR. New Journal of Chemistry, 2018, 42, 10761-10773.	1.4	8
16	In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 59-74.	1.4	36
17	First report on the pharmacokinetic profile of nimbolide, a novel anticancer agent in oral and intravenous administrated rats by LC/MS method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1092, 191-198.	1.2	30
18	LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 92-99.	1.4	11

#	Article	IF	Citations
19	Characterization of Forced Degradation Products of Rufinamide by LC/QTOF/MS/MS, NMR and IR studies. Analytical Chemistry Letters, 2018, 8, 405-415.	0.4	4
20	Identification and characterization of fluvastatin metabolites in rats by UHPLC/Q‶OF/MS/MS and <i>in silico</i> toxicological screening of the metabolites. Journal of Mass Spectrometry, 2017, 52, 296-314.	0.7	8
21	Characterization of degradation products of regorafenib by LC-QTOF-MS and NMR spectroscopy: investigation of rearrangement and odd-electron ion formation during collision-induced dissociations under ESI-MS/MS. New Journal of Chemistry, 2017, 41, 12091-12103.	1.4	8
22	Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahighâ€performance liquid chromatography/quadrupole timeâ€ofâ€flight tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2017, 31, 1974-1984.	0.7	13
23	Automated statistical experimental design approach for rapid separation of coenzyme Q10 and identification of its biotechnological process related impurities using UHPLC and UHPLC–APClâ€MS. Journal of Separation Science, 2016, 39, 3528-3535.	1.3	2
24	Selective separation and characterisation of stress degradation products and process impurities of prucalopride succinate by LC-QTOF-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 219-228.	1.4	16
25	Characterization of forced degradation products of pazopanib hydrochloride by UHPLCâ€Q‶OF/MS and <i>in silico</i> toxicity prediction. Journal of Mass Spectrometry, 2015, 50, 918-928.	0.7	11
26	Rapid structural characterization of <i>in vivo</i> and <i>in vitro</i> metabolites of tinoridine using UHPLC–QTOF–MS/MS and <i>in silico</i> toxicological screening of its metabolites. Journal of Mass Spectrometry, 2015, 50, 1222-1233.	0.7	24
27	Protonated <i>N</i> â€benzyl―and <i>N</i> â€(1â€phenylethyl)tyrosine amides dissociate via ion/neutral complexes. Rapid Communications in Mass Spectrometry, 2015, 29, 1577-1584.	0.7	7
28	Quality by design based development of a selective stability-indicating UPLC method of dolutegravir and characterization of its degradation products by UPLC-QTOF-MS/MS. New Journal of Chemistry, 2015, 39, 6303-6314.	1.4	20
29	LC–MS-MS Characterization of Forced Degradation Products of Fidarestat, a Novel Aldose Reductase Inhibitor: Development and Validation of a Stability-Indicating RP-HPLC Method. Journal of Chromatographic Science, 2015, 53, 1588-1596.	0.7	2
30	Isolation, LC–MS/MS and 2D-NMR characterization of alkaline degradants of tenofovir disoproxil fumarate. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 175-185.	1.4	14
31	A validated liquid chromatography mass spectrometry method for the quantification of tinoridine hydrochloride in rat plasma and its application to pharmacokinetic studies. Analytical Methods, 2015, 7, 1965-1970.	1.3	1
32	Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS/MS and in silico toxicity predictions of its degradation products. RSC Advances, 2015, 5, 31024-31038.	1.7	20
33	Characterization of stress degradation products of blonanserin by UPLC-QTOF-tandem mass spectrometry. RSC Advances, 2015, 5, 69273-69288.	1.7	6
34	Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC/ESI/QTOF/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 1-9.	1.4	18
35	Identification of hydrolytic and isomeric N-oxide degradants of vilazodone by on line LC–ESI–MS/MS and APCI–MS. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 353-365.	1.4	28
36	Design and study of a HPLC method for the simultaneous estimation of two anti-diabetic drugs using a statistical approach. Analytical Methods, 2014, 6, 3291.	1.3	3

#	Article	IF	CITATIONS
37	Improvement of Bioavailability and Anti-Inflammatory Potential of Curcumin in Combination with Emu Oil. Inflammation, 2014, 37, 2139-2155.	1.7	25
38	Experimental Design Approach for Selective Separation of Vilazodone HCl and Its Degradants by LC-PDA and Characterization of Major Degradants by LC/QTOF–MS/MS. Chromatographia, 2014, 77, 1299-1313.	0.7	12
39	Quality by design: A systematic and rapid liquid chromatography and mass spectrometry method for eprosartan mesylate and its related impurities using a superficially porous particle column. Journal of Separation Science, 2014, 37, 2160-2171.	1.3	13
40	Selective separation, detection of zotepine and mass spectral characterization of degradants by LC–MS/MS/QTOF. Journal of Pharmaceutical Analysis, 2014, 4, 107-116.	2.4	14
41	Synchronized separation of atorvastatin—an antihyperlipidemic drug with antihypertensive, antidiabetic, antithrombotic drugs by RP-LC for determination in combined formulations. Journal of Pharmaceutical Analysis, 2012, 2, 285-292.	2.4	6
42	DEVELOPMENT AND VALIDATION OF RP-HPLC AND ULTRAVIOLET SPECTROPHOTOMETRIC METHODS OF ANALYSIS FOR SIMULTANEOUS DETERMINATION OF PARACETAMOL AND LORNOXICAM IN PHARMACEUTICAL DOSAGE FORMS. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 129-140.	0.5	16
43	LC–ESI-MS determination and pharmacokinetics of adrafinil in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 873, 119-123.	1.2	10
44	Development of a validated RP-LC/ESI-MS–MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 94-103.	1.4	23
45	Continuous counter current extraction, isolation and determination of solanesol in Nicotiana tobacum L. by non-aqueous reversed phase high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 310-315.	1.4	22
46	Development and validation of a reversed phase liquid chromatographic method for separation and determination of related-substances of modafinil in bulk drugsa~†. Talanta, 2007, 73, 407-414.	2.9	14
47	An overview of recent applications of inductively coupled plasma-mass spectrometry (ICP-MS) in determination of inorganic impurities in drugs and pharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1-13.	1.4	134